Changes to injectable weight loss medicines

The landscape for glucagon-like peptide-1 receptor agonists (GLP-1RAs) used for weight loss is changing in Australia as demand continues to grow.

Intranasal vaccine stops infection at the source

Administered to the nasal mucosa, a spike-based formulation triggers rapid local defences that clear the COVID-19 virus where it enters. In 2022, a year after...

Helping patients understand new vaping restrictions

With additional vaping restrictions rolling out throughout 2024, more patients will likely seek therapeutic vaping products.

How to identify the most accurate RATs

Find out which COVID-19 rapid antigen tests are the best-performing, and what product has failed to detect the virus.

TGA issues two new safety alerts for GLP-1 RA products

The Therapeutic Goods Administration (TGA) has today (Monday 1 December) made updates to product warnings for GLP-1 and dual GIP/GLP-1 receptor agonists for two...

Supporting patients through GLP-1 agonist cessation effects

Glucagon-like peptide 1 (GLP-1) agonists, traditionally used to manage type 2 diabetes, have been increasingly prescribed off-label for weight loss.  There are four GLP-1 agonist...